Drug Profile
Research programme: anticancer antibody-drug conjugates - Asana BioSciences
Alternative Names: ASN005Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Asana BioSciences
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 02 Dec 2015 Preclinical trials in Cancer in USA (IV)